News Archives - Page 62 of 705

WednesdayAug 21, 2024 9:45 am

National Investment Banking Association 150th Investment Conference Comes to Ft. Lauderdale, Florida

The National Investment Banking Association (“NIBA”) invites the micro-cap and small-cap investment community to its 150th investment conference. The event will be held on September 4-5, 2024, at the Westin Fort Lauderdale Beach Resort, Ft. Lauderdale, Florida. Since 1982, The National Investment Banking Association has been a not-for-profit association for the micro-cap and small-cap investment community and has hosted 149 investment conferences featuring public and private micro-cap and small-cap companies seeking access to the financial industry. NIBA’s member firms have a 40 year track record of successfully completing thousands of transactions totaling over $80 billion in new capital for emerging…

WednesdayAug 21, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Reports Strong Q2 2024 Results

The company reported a 28% increase in revenue, a 6% rise in bookings, a 97% improvement in GAAP gross profit and a 444% increase in cash, for the second quarter of 2024, on a year over year basis D-Wave's CEO, Dr. Alan Baratz, summarized the company's ongoing strategic direction and provided an expansive list of achievements Highlights mentioned include a quantum AI product development roadmap extending D-Wave’s Leap(TM) quantum cloud service, an expanded partnership with Zapata AI, new customer hybrid quantum applications, and more D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first…

TuesdayAug 20, 2024 11:01 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Exciting INM-901 Data Providing ‘Attractive Therapeutic Approach’ in Alzheimer’s Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical studies confirms INM-901, a proprietary small molecule drug candidate, as an oral formulation that will be utilized in the company’s development programs for Alzheimer’s disease. The data shows that the INM-901 formulation can be administered orally and maintains similar drug exposure and therapeutic levels as intraperitoneal (“IP”) delivery over a 24-hour period in the brain. The announcement noted that the oral delivery method offers potential advantages such as lower treatment delivery costs. “We are…

TuesdayAug 20, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association…

MondayAug 19, 2024 10:30 am

SenesTech Inc. (NASDAQ: SNES) Offers a Sustainable and Environmentally-Friendly Solution to the Growing Rodent Problem where Poisons and Traps Have Failed

SenesTech, a rodent fertility control product provider and the inventor of the only EPA-registered contraceptive for male and female rats, is offering a sustainable and proactive tool in the fight against rodent pests With New York City reporting an estimated 3 million rats as one of the top five list of the most rat-infested cities in the U.S., it paints a grim picture of the situation at hand SenesTech’s Evolve(TM) soft bait products for both rats and mice has been scientifically proven to manage rodent infestations, allowing for a superior proactive approach to addressing the rodent problem The product was…

MondayAug 19, 2024 9:45 am

Canada’s Resource Rich Future: Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Taking Canada Beyond Oil & Gold

Canada is recognized globally as an oil and gold powerhouse, but the country is also a world leader in other metals, a trend that looks to be gaining steam With strategic acquisitions, Fathom Nickel has assembled a dominant land position in Saskatchewan’s Trans-Hudson Corridor, positioning the company to become a leading nickel provider in the sustainable energy market Data continues to show mineralization open on strike and at depth, with evidence that the deposits may be interconnected as part of one massive system A surge in exports in June confounded pundits that called for Canada to experience a fourth straight…

MondayAug 19, 2024 9:00 am

ECGI Holdings Inc. (ECGI) to Leverage AI-Driven Technologies for ‘Extraordinary Advancements’ in Unique Retail Areas

ECGI Holdings is a diversified holding company with a unique portfolio in viticulture, hospitality, and luxury fashion The company’s subsidiary Pacific Saddlery is looking to introduce technologies that leverage AI capabilities to provide customer fit recommendations amid plans to launch a new line of ready-to-wear apparel under its Allon brand The company believes AI-powered solutions will help increase conversion rates, reduce return rates, and enhance customer engagement and loyalties Apparel manufacturers and online apparel brands are turning to AI-driven technologies to reduce returns and their impact on the bottom line A 2023 study listed size/fit, color, and damage as the…

FridayAug 16, 2024 10:36 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment

Lexaria, a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM) technology for the oral delivery of glucagon-like peptide-1 (“GLP-1”) drugs. GLP-1 drugs have shown great promise in addressing diabetes and obesity, with nearly all the major brands administered only through injection devices. A previous human study by Lexaria evidenced improved bioavailability when semaglutide was administered orally, as compared to standard Rybelsus®. Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP1 market. Data…

Site Search

Company Search

Category: News